Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Shares Purchased by Public Employees Retirement System of Ohio

Public Employees Retirement System of Ohio increased its position in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 13.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 75,648 shares of the biopharmaceutical company’s stock after acquiring an additional 9,100 shares during the quarter. Public Employees Retirement System of Ohio owned approximately 0.13% of Vanda Pharmaceuticals worth $327,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Envestnet Asset Management Inc. lifted its position in Vanda Pharmaceuticals by 11.4% in the third quarter. Envestnet Asset Management Inc. now owns 11,210 shares of the biopharmaceutical company’s stock valued at $111,000 after buying an additional 1,146 shares during the last quarter. Yousif Capital Management LLC lifted its position in Vanda Pharmaceuticals by 2.4% in the first quarter. Yousif Capital Management LLC now owns 50,710 shares of the biopharmaceutical company’s stock valued at $574,000 after buying an additional 1,180 shares during the last quarter. Legal & General Group Plc lifted its position in Vanda Pharmaceuticals by 0.9% in the second quarter. Legal & General Group Plc now owns 134,874 shares of the biopharmaceutical company’s stock valued at $1,471,000 after buying an additional 1,223 shares during the last quarter. Tower Research Capital LLC TRC lifted its position in Vanda Pharmaceuticals by 91.4% in the second quarter. Tower Research Capital LLC TRC now owns 5,538 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 2,644 shares during the last quarter. Finally, CWM LLC lifted its position in Vanda Pharmaceuticals by 61.1% in the third quarter. CWM LLC now owns 7,205 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 2,732 shares during the last quarter. Institutional investors and hedge funds own 88.14% of the company’s stock.

Vanda Pharmaceuticals Price Performance

Shares of NASDAQ:VNDA opened at $3.89 on Thursday. The firm has a market capitalization of $223.83 million, a PE ratio of 77.82 and a beta of 0.77. The firm’s 50-day moving average is $3.99 and its two-hundred day moving average is $4.07. Vanda Pharmaceuticals Inc. has a 1 year low of $3.30 and a 1 year high of $7.00.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings results on Wednesday, February 7th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.05. Vanda Pharmaceuticals had a net margin of 1.30% and a return on equity of 0.46%. The company had revenue of $45.27 million for the quarter, compared to analyst estimates of $37.00 million. Analysts expect that Vanda Pharmaceuticals Inc. will post 0.01 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have commented on VNDA. StockNews.com cut shares of Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, February 28th. TheStreet cut shares of Vanda Pharmaceuticals from a “c-” rating to a “d” rating in a research report on Thursday, February 8th.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.